INmune Bio, Inc. to Present at the H.C. Wainwright Global Hybrid Investment Conference on May 24th
INmune Bio (NASDAQ: INMB) announced that David Moss, CFO, will present at the H.C. Wainwright Global Hybrid Investment Conference from May 23-26, 2022, at the Fontainebleau Hotel in Miami Beach, FL. The presentation is scheduled for May 24, 2022, at 10:00 AM ET. Moss will also be available for one-on-one meetings, which can be requested through the conference registration link. INmune Bio is focused on immunological therapies targeting the innate immune system, with several candidates in clinical trials for various conditions.
- None.
- None.
Boca Raton, FL, May 18, 2022 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical stage immunology company focused on developing treatments that harness the patient’s immune system to fight disease, announced today that David Moss, Chief Financial Officer will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The conference is being held on May 23 – 26, 2022 at the Fontainebleau Hotel in Miami Beach, FL.
Presentation Date: May 24, 2022
Time: 10:00am ET
Mr. Moss will be available for one-on-one meetings. To request a meeting and to register for the conference, click here:
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO
(858) 964-3720
info@inmunenbio.com
FAQ
When is David Moss presenting at the H.C. Wainwright Global Hybrid Investment Conference for INmune Bio?
What is the focus of INmune Bio's clinical trials?
Where is the H.C. Wainwright Global Hybrid Investment Conference being held?
How can investors request a one-on-one meeting with David Moss at the conference?
What stock symbol is associated with INmune Bio?
